CA2985184C - Agents thearapeutiques et agents d'imagerie compagnons ciblant le mc1r - Google Patents

Agents thearapeutiques et agents d'imagerie compagnons ciblant le mc1r

Info

Publication number
CA2985184C
CA2985184C CA2985184A CA2985184A CA2985184C CA 2985184 C CA2985184 C CA 2985184C CA 2985184 A CA2985184 A CA 2985184A CA 2985184 A CA2985184 A CA 2985184A CA 2985184 C CA2985184 C CA 2985184C
Authority
CA
Canada
Prior art keywords
cancer
disclosed
compounds
mc1r
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2985184A
Other languages
English (en)
Other versions
CA2985184A1 (fr
Inventor
David Morse
Robert Gillies
Mark McLaughlin
Thaddeus WADAS
Hyun Joo KIL
Narges TAFRESHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Modulation Therapeutics Inc
Wake Forest University
H Lee Moffitt Cancer Center and Research Institute Inc
University of South Florida St Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modulation Therapeutics Inc, Wake Forest University, H Lee Moffitt Cancer Center and Research Institute Inc, University of South Florida St Petersburg filed Critical Modulation Therapeutics Inc
Priority claimed from PCT/US2016/031290 external-priority patent/WO2016179529A2/fr
Publication of CA2985184A1 publication Critical patent/CA2985184A1/fr
Application granted granted Critical
Publication of CA2985184C publication Critical patent/CA2985184C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention se rapporte d'une manière générale à la cancérothérapie ainsi qu'aux composés anticancéreux et aux agents d'imagerie. Plus spécifiquement, l'invention concerne des agents qui ciblent le MC1R et leur utilisation dans le traitement du cancer. L'invention concerne également des procédés de criblage d'agents ciblant le MC1R.
CA2985184A 2015-05-06 2016-05-06 Agents thearapeutiques et agents d'imagerie compagnons ciblant le mc1r Active CA2985184C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562157784P 2015-05-06 2015-05-06
US62/157,784 2015-05-06
PCT/US2016/031290 WO2016179529A2 (fr) 2015-05-06 2016-05-06 Agents théarapeutiques et agents d'imagerie compagnons ciblant le mc1r

Publications (2)

Publication Number Publication Date
CA2985184A1 CA2985184A1 (fr) 2016-11-10
CA2985184C true CA2985184C (fr) 2025-09-23

Family

ID=

Similar Documents

Publication Publication Date Title
US12269837B2 (en) Bifunctional do2pa derivatives, chelates with metallic cations and use thereof
AU2019234468B2 (en) Bispecific binding agents and uses thereof
US20250367312A1 (en) Delta-opioid receptor targeted agent for molecular imaging and immunotherapy of cancer
Schubert et al. Novel tumor pretargeting system based on complementary l-configured oligonucleotides
US12508329B2 (en) Radiotherapeutic and companion imaging agents to target MC1R
US8562947B2 (en) Oxidized avidin with high residency time in the treated tissues
CA2985184C (fr) Agents thearapeutiques et agents d'imagerie compagnons ciblant le mc1r
WO2026036076A1 (fr) Agents radiothérapeutiques et agents d'imagerie compagnons
US20240207458A1 (en) Targeted alpha particle therapy for somatostatin receptor 2 positive neuroendocrine tumors and metastases
WO2022187812A1 (fr) Agent ciblant le récepteur aux opioïdes de type delta pour imagerie moléculaire et immunothérapie du cancer